doravirine
Selected indexed studies
- Doravirine: its role in HIV treatment. (Curr Opin HIV AIDS, 2022) [PMID:34740228]
- Doravirine/islatravir for the treatment of HIV. (Expert Opin Pharmacother, 2025) [PMID:39651697]
- Doravirine. (, 2012) [PMID:31643591]
_Worker-drafted node — pending editorial review._
Connections
doravirine is a side effect of
Sources
- Doravirine: its role in HIV treatment. (2022) pubmed
- Doravirine/islatravir for the treatment of HIV. (2025) pubmed
- Doravirine. (2012) pubmed
- Doravirine: a review. (2018) pubmed
- Doravirine: First Global Approval. (2018) pubmed
- Doravirine: A Return of the NNRTI Class? (2020) pubmed
- Doravirine. (2006) pubmed
- Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial. (2025) pubmed
- Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials. (2024) pubmed
- Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection. (2020) pubmed